CN104072476B — 泊马度胺晶型及其制备方法和用途
Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2018-08-21 · 8y expired
What this patent protects
本发明涉及泊马度胺晶型及其制备方法和用途。具体而言,本发明公开了一种泊马度胺晶型、其制备方法、其药物组合物及其制药用途。该泊马度胺晶型的X射线粉末衍射图具有2θ(±0.2°)特征峰:12.08,12.62,13.90,17.13,18.30,22.81,24.24,25.48,27.87。本发明所提供的泊马度胺晶型性状稳定,可重复性好,适合药物开发。
USPTO Abstract
本发明涉及泊马度胺晶型及其制备方法和用途。具体而言,本发明公开了一种泊马度胺晶型、其制备方法、其药物组合物及其制药用途。该泊马度胺晶型的X射线粉末衍射图具有2θ(±0.2°)特征峰:12.08,12.62,13.90,17.13,18.30,22.81,24.24,25.48,27.87。本发明所提供的泊马度胺晶型性状稳定,可重复性好,适合药物开发。
Drugs covered by this patent
- Revlimid (lenalidomide) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.